TREATPOLYQ
TreatPolyQ – Industrial Academic Initial Training Network towards treatment of Polyglutamine Diseases
| Coordinatore | EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙757˙318 € |
| EC contributo | 3˙757˙318 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2010-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-03-01 - 2015-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | coordinator | 533˙510.00 |
| 2 |
H. LUNDBECK A/S
Organization address
address: Ottiliavej 9 contact info |
DK (VALBY) | participant | 281˙488.00 |
| 3 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 261˙223.00 |
| 4 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 261˙223.00 |
| 5 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 260˙042.00 |
| 6 |
UNIVERSITE PARIS DIDEROT - PARIS 7
Organization address
address: RUE THOMAS MANN 5 contact info |
FR (PARIS) | participant | 257˙129.00 |
| 7 |
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Organization address
address: TECHNION CITY - SENATE BUILDING contact info |
IL (HAIFA) | participant | 251˙385.00 |
| 8 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 246˙392.00 |
| 9 |
INSTITUT CURIE
Organization address
address: 26, rue d'Ulm contact info |
FR (PARIS) | participant | 246˙392.00 |
| 10 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 246˙099.00 |
| 11 |
SIENA BIOTECH SPA
Organization address
address: Via Banchi di Sotto 34 contact info |
IT (SIENA) | participant | 240˙518.00 |
| 12 |
AC IMMUNE SA
Organization address
address: "Parc Scientifique EPFL, PSE B" contact info |
CH (Lausanne) | participant | 238˙461.00 |
| 13 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 222˙015.00 |
| 14 |
CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO
Organization address
address: UNIVERSIDADE DE COIMBRA . contact info |
PT (COIMBRA) | participant | 211˙441.00 |
| 15 |
ENKAM PHARMACEUTICALS A/S
Organization address
address: "Fruebjergvej, 3" contact info |
DK (COPENHAGEN) | participant | 0.00 |
| 16 |
NsGene A/S
Organization address
address: BALTORPVEJ 154 contact info |
DK (BALLERUP) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of model diseases and treatment approaches. The “TreatPolyQ” network will focus on two main representatives of the polyQ diseases: Huntington’s disease as the most common polyQ disease as well as spinocerebellar ataxia type 3 (SCA3) as the most frequent autosomal-dominantly inherited ataxia. Patients suffer from a multitude of neurological symptoms including movement abnormalities with late onset and in a progressive manner. Up to now, no treatment or cure is available. The network will be consisting of a rare combination of experts from basic and translational research, including a Nobel prize laureate, four industrial partners (two medium, and two small companies, all incorporated as full participants) and academic leaders of the field. The network not only focuses on one special aspect of a disease but spans several important disease-associated mechanism as well as promising treatment strategies for HD and SCA3 (protein transport, protein folding, protein degradation via both the ubiquitin-proteasome system and autophagy), likely to be important across a range of neurodegenerative diseases. In order to implement these research projects, extensive collaborations and temporarily personnel secondments of the involved researchers will take place, enhancing interdisciplinary transfer of knowledge. Beyond the personalized local training plan for each employed researcher within the Network, there will be 4 structured courses covering aspects ranging from structural biology to protein degradation to model organisms and drug development, including soft skill training.'